Business
Diaceutics launches daily alerts for DXRX platform
Diaceutics launches daily alerts for DXRX platform.
About this update from Diaceutics Plc
[{"type":"text","content":"\n\nRNS Reach\n29 August 2023\n \n \nDiaceutics launches daily alerts for DXRX platform\n \nDaily alerts will enable pharma clients to identify patients previously not receiving the most appropriate treatment due to lack of timely data\n \nDiaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, is pleased to announce an important and innovative upgrade to its DXRX platform which sees the Company's DXRX Signal product now providing alerts on a daily basis. This ground-breaking innovation will provide Diaceutics' customers with even more timely data to identify patients who would benefit from their therapies and improve their commercial success. For patients, it means their chances of receiving the optimal therapy within the window of effectiveness is significantly improved.\n \nDXRX Signal utilizes real-world data collected from a diverse network of over ~500 labs, encompassing academic, community, and commercial facilities. This comprehensive data pool ensures supply chain reliability and encompasses both geographical and clinical diversity. For Diaceutics' customers, this translates into extensive coverage across a spectrum of medical conditions, including oncology, rare diseases, auto-immune disorders, cardiovascular and infectious diseases.\n \nDXRX Signal has identified over 46,000 patients so far in 2023 for its biopharma clients.\n \nBuilding upon the foundation of DXRX Signal, Diaceutics has introduced this pivotal enhancement. These alerts, now available on a daily basis, empower Diaceutics' customers with even timelier insights as they deploy products to pinpoint patients and elevate their commercial success. This innovation equips healthcare professionals with crucial data on a daily basis, and within days of a positive test result. With increased timely access to diagnostic information, physicians can be engaged precisely during the treatment decision window, ensuring the most effective drugs or therapies are offered promptly to patients.\n \nIn 2022, the 'Practice Gaps Study' highlighted the existence of seven distinct clinical practice gaps. These gaps collectively contributed to a concerning statistic: 64.4% of cancer patients did not receive the appropriate targeted therapy, of which, 29.2% of patients were lost at the critical...